Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trimetazidine for myalgic encephalomyelitis/chronic fatigue syndrome
ACTRN12625000095460Phase 3Recruiting
- Sponsor
- Deakin University
- Start
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in myalgic encephalomyelitis (ME) comparing Trimetazidine with Matched placebo (2 arms). Primary endpoint: Between-group differential change in ME/CFS symptoms on the Chalder Fatigue Scale. Started Jul 2025; status: recruiting.
02
Drugs
trimetazidine
03
Conditions
myalgic encephalomyelitis (ME)
Beyond the preview
Go deeper on ACTRN12625000095460.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12625000095460.